Tokyo, Japan

Masayasu Yoshino


 

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2016-2018

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Masayasu Yoshino: Innovator in Cancer Treatment

Introduction

Masayasu Yoshino is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. With a total of 4 patents, Yoshino's work focuses on developing methods to combat cancer and related diseases.

Latest Patents

Yoshino's latest patents include groundbreaking methods for treating cancer by inhibiting the FGFR3/TACC3 fusion protein. This invention aims to identify a novel polynucleotide responsible for cancer, providing a method for its detection along with a corresponding polypeptide and a detection kit. The invention also includes a pharmaceutical composition designed to treat cancer by targeting the fusion gene or the polypeptide associated with it. Another significant patent involves the development of an anti-human PAI-1 antibody, which is intended to prevent or treat pulmonary fibrosis by inhibiting the effects mediated by active human PAI-1.

Career Highlights

Masayasu Yoshino is currently associated with Astellas Pharma GmbH, where he continues to advance his research in the pharmaceutical field. His work has garnered attention for its potential impact on cancer therapies and treatment methodologies.

Collaborations

Yoshino collaborates with notable colleagues, including Atsushi Suzuki and Makoto Asaumi, to further enhance the scope and effectiveness of his research.

Conclusion

Masayasu Yoshino's innovative contributions to cancer treatment exemplify the vital role of inventors in advancing medical science. His patents reflect a commitment to improving patient outcomes and addressing critical health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…